As NK cell and CD8+ T cell expression of TIGIT increases with acute HIV-1 infection, introducing mAb therapy to overcome the higher affinity TIGIT/PVR inhibitory interaction in favor of DNAM-1/PVR-mediated activation is a rational strategy to address lingering HIV-1 infection (Yin et al., 2018). This evidence concerns the gene CD8A and HIV-1 infection.